Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Recommendation of “Buy” from Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have issued a strong buy recommendation on the company.

Several brokerages recently issued reports on ZLDPF. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday, December 16th.

Zealand Pharma A/S Trading Up 6.7%

Shares of Zealand Pharma A/S stock opened at $67.80 on Friday. The firm’s 50 day moving average is $74.43 and its 200 day moving average is $69.34. The firm has a market capitalization of $4.81 billion, a PE ratio of 4.88 and a beta of 0.74. Zealand Pharma A/S has a 1 year low of $49.98 and a 1 year high of $110.00. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.21. The firm had revenue of $7.76 million for the quarter, compared to analyst estimates of $4.54 million. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. Equities research analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.